# Pasithea Therapeutics Corp. (KTTA)

Source: https://www.quantisnow.com/company/KTTA
Generated: 2026-11-15T15:50:10.876Z

- Ticker: KTTA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001841330

## Latest KTTA news and filings

- 2026-11-13 22:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pasithea-therapeutics-corp-6791439)
- 2026-11-13 07:00 UTC [Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference](https://www.quantisnow.com/insight/pasithea-therapeutics-presents-positive-initial-phase-11b-data-for-pas-004-6789144)
- 2026-11-06 21:05 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pasithea-therapeutics-corp-6778851)
- 2026-11-03 12:00 UTC [Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-fda-clearance-of-ind-for-pas-004-in-6768329)
- 2026-10-28 20:05 UTC [Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026](https://www.quantisnow.com/insight/pasithea-therapeutics-to-host-virtual-kol-event-on-nf1-treatment-6761152)
- 2026-10-23 13:15 UTC [Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-positive-pas-004-clinical-data-from-phase-1-6756004)
- 2026-09-16 20:06 UTC [SEC Form 8-K] [Pasithea Therapeutics Corp. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/pasithea-therapeutics-corp-filed-sec-form-8-k-other-events-6717495)
- 2026-09-16 20:04 UTC [SEC Form 25-NSE filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-pasithea-therapeutics-corp-6717445)
- 2026-09-14 11:00 UTC [Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-presentation-of-initial-pas-004-clinical-data-from-6713644)
- 2026-09-09 20:20 UTC [SEC Form 8-K] [Pasithea Therapeutics Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pasithea-therapeutics-corp-filed-sec-form-8-k-submission-of-matters-6710134)
- 2026-09-03 20:05 UTC [Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-participation-in-two-september-2026-investor-conferences-6704941)
- 2026-08-21 21:05 UTC [SEC Form 8-K] [Pasithea Therapeutics Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/pasithea-therapeutics-corp-filed-sec-form-8-k-notice-of-delisting-6691670)
- 2026-08-14 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pasithea-therapeutics-corp-6683222)
- 2026-08-07 21:15 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-pasithea-therapeutics-corp-6672123)
- 2026-07-31 20:05 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pasithea-therapeutics-corp-6657776)
- 2026-07-29 21:15 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-pasithea-therapeutics-corp-6654290)
- 2026-07-21 11:00 UTC [Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-european-society-6643125)
- 2026-07-08 11:02 UTC [Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle-6630835)
- 2026-06-30 11:00 UTC [Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-6619889)
- 2026-06-23 21:40 UTC [SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-pasithea-therapeutics-corp-6613110)
- 2026-06-22 14:30 UTC [Insider Buy] [Large owner Coastlands Capital Lp bought $53,000 worth of shares (100,000 units at $0.53) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-coastlands-capital-lp-bought-53000-worth-of-shares-6610390)
- 2026-06-16 11:00 UTC [Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-amendments-to-clinical-study-protocol-for-phase-6603811)
- 2026-06-15 11:02 UTC [Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-exhibit-at-childrens-tumor-foundation-2026-nf-6601765)
- 2026-06-02 11:02 UTC [Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-orphan-drug-designation-by-fda-of-pas-004-6583103)
- 2026-05-15 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pasithea-therapeutics-corp-6557808)
- 2026-05-15 14:20 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pasithea-therapeutics-corp-6556298)
- 2026-05-05 20:42 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Marques Tiago](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-marques-tiago-6532836)
- 2026-05-05 20:41 UTC [SEC Form 4] [SEC Form 4 filed by Director Dumesnil Simon](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dumesnil-simon-6532832)
- 2026-05-05 20:42 UTC [SEC Form 4] [SEC Form 4 filed by Director Steinman Lawrence](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-steinman-lawrence-6532831)
- 2026-05-05 20:41 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Schneiderman Daniel H](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-schneiderman-daniel-6532828)
- 2026-05-05 20:41 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Krishnan Kartik](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-krishnan-kartik-6532825)
- 2026-05-05 20:41 UTC [SEC Form 4] [SEC Form 4 filed by Director Leahy Emer](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-leahy-emer-6532822)
- 2026-05-05 20:40 UTC [SEC Form 4] [SEC Form 4 filed by Director Novak Alfred J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-novak-alfred-j-6532820)
- 2026-05-05 20:38 UTC [SEC Form 3] [SEC Form 3 filed by new insider Krishnan Kartik](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-krishnan-kartik-6532802)
- 2026-05-04 21:00 UTC [SEC Form 8-K] [Pasithea Therapeutics Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pasithea-therapeutics-corp-filed-sec-form-8-k-leadership-update-regulation-6529653)
- 2026-05-04 11:01 UTC [Leadership Update] [Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-appointment-of-kartik-krishnan-md-phd-as-6527912)
- 2026-04-20 11:01 UTC [Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-grant-of-rare-pediatric-disease-designation-rpdd-6505912)
- 2026-04-18 01:45 UTC [SEC Form 3] [SEC Form 3 filed by new insider Coastlands Capital Lp](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-coastlands-capital-lp-6505662)
- 2026-04-09 00:25 UTC [SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-pasithea-therapeutics-corp-6493548)
- 2026-04-01 11:01 UTC [Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity](https://www.quantisnow.com/insight/pasithea-therapeutics-announces-grant-of-fast-track-designation-by-fda-6480663)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KTTA
- Earnings history: https://www.quantisnow.com/earnings/KTTA
- Dividend history: https://www.quantisnow.com/dividends/KTTA
- Insider transactions: https://www.quantisnow.com/insiders/KTTA
- Options chain: https://www.quantisnow.com/options/KTTA
- SEC 8-K filings only: https://www.quantisnow.com/company/KTTA/8-k
- RSS and alerts for KTTA: https://www.quantisnow.com/docs/rss-feeds.md